865 related articles for article (PubMed ID: 11691681)
1. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
Glassman AH; Bigger JT
Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
3. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
Taylor D
CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
[TBL] [Abstract][Full Text] [Related]
4. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
5. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
Gury C; Canceil O; Iaria P
Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
[TBL] [Abstract][Full Text] [Related]
6. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic drugs and QT interval prolongation.
Zareba W; Lin DA
Psychiatr Q; 2003; 74(3):291-306. PubMed ID: 12918603
[TBL] [Abstract][Full Text] [Related]
8. Prolonged QT Risk Assessment in Antipsychotic Overdose Using the QT Nomogram.
Berling I; Isbister GK
Ann Emerg Med; 2015 Aug; 66(2):154-64. PubMed ID: 25639523
[TBL] [Abstract][Full Text] [Related]
9. QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy.
Feldman AE; Gidal BE
Epilepsy Behav; 2013 Mar; 26(3):421-6. PubMed ID: 23218812
[TBL] [Abstract][Full Text] [Related]
10. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.
Titier K; Girodet PO; Verdoux H; Molimard M; Bégaud B; Haverkamp W; Lader M; Moore N
Drug Saf; 2005; 28(1):35-51. PubMed ID: 15649104
[TBL] [Abstract][Full Text] [Related]
12. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.
Michalets EL; Smith LK; Van Tassel ED
Ann Pharmacother; 1998; 32(7-8):761-5. PubMed ID: 9681092
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol-induced torsade de pointes.
O'Brien JM; Rockwood RP; Suh KI
Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
[TBL] [Abstract][Full Text] [Related]
14. QT alterations in psychopharmacology: proven candidates and suspects.
Alvarez PA; Pahissa J
Curr Drug Saf; 2010 Jan; 5(1):97-104. PubMed ID: 20210726
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the potential of clozapine to cause torsade de pointes.
Warner B; Hoffmann P
Adverse Drug React Toxicol Rev; 2002; 21(4):189-203. PubMed ID: 12503253
[TBL] [Abstract][Full Text] [Related]
16. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.
Vieweg WV; Wood MA
Psychosomatics; 2004; 45(5):371-7. PubMed ID: 15345781
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
18. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.
Vieweg WV; Schneider RK; Wood MA
Acta Psychiatr Scand; 2005 Oct; 112(4):318-22; author reply 322. PubMed ID: 16156840
[TBL] [Abstract][Full Text] [Related]
19. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
Zeltser D; Justo D; Halkin A; Prokhorov V; Heller K; Viskin S
Medicine (Baltimore); 2003 Jul; 82(4):282-90. PubMed ID: 12861106
[TBL] [Abstract][Full Text] [Related]
20. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
